Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Olmesartan Medoxomil
Olmesartan Medoxomil and Hydrochlorothiazide · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Benicar HCT ® Tablets 40 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg | DRUG | - |
| Benicar HCT ® Tablets 40 mg/25 mg | DRUG | - |
| Benicar HCT® Tablets 40 mg/25 mg | DRUG | - |
| Olmesartan Medoxomil Tablets 40 mg | DRUG | 40mg, single dose fed |
| Benicar® Tablets 40 mg | DRUG | 40mg, single dose fed |
Inclusion Criteria: * healthy, adult subjects, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days of start of study * received any investigational product...
Olmesartan Medoxomil and Hydrochlorothiazide is a small molecule combination product developed by Viatris Inc. (VTRS). It combines olmesartan medoxomil, an AGTR1 antagonist, with hydrochlorothiazide. The program has been studied in Phase 1 clinical trials, all of which are completed, with a total enrollment of 144 participants across four studies.
Olmesartan Medoxomil and Hydrochlorothiazide targets AGTR1, the angiotensin II receptor type 1. Olmesartan medoxomil acts as an antagonist at this receptor. Hydrochlorothiazide is a thiazide diuretic. The combination is designed to lower blood pressure through these complementary mechanisms.
Olmesartan Medoxomil and Hydrochlorothiazide is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the sponsor of the clinical program for this combination product.
Olmesartan Medoxomil and Hydrochlorothiazide is in Phase 1 clinical development. All four of its Phase 1 trials are completed, and none are currently active. The program has enrolled 144 participants in total. It remains an investigational product and is not approved by the FDA for any indication.
Olmesartan Medoxomil and Hydrochlorothiazide has been evaluated in four completed Phase 1 trials: NCT01020214 (fasting study), NCT01019590 (fed study), NCT00649623 (fasting study of olmesartan medoxomil tablets), and NCT00648219 (fed study of olmesartan medoxomil tablets). All enrolled healthy volunteers in the United States.
Olmesartan Medoxomil and Hydrochlorothiazide is a combination product that contains olmesartan medoxomil plus hydrochlorothiazide. Olmesartan Medoxomil alone is a separate product. The alternative names for this combination include Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Olmesartan Medoxomil Tablets 40 mg.